Page 1

Schedule-at-a-Glance


In asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer

Before, Frank's immune cells could

barely recognize a prostate cancer cell.

Now, they are focused on it.


PROVENGE is the first in a new class of therapy that is designed to activate a patient’s own antigen-presenting cells to stimulate an immune response against prostate cancer.

➜ For more information on PROVENGE, please visit us at BOOTH 3713 ➜ You can receive an e-subscription to Campbell-Walsh UROLOGY at the booth

INDICATION: PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. IMPORTANT SAFETY INFORMATION: PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases. In controlled clinical trials, serious adverse events reported in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group. The most common adverse events (incidence ≥15%) reported in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Please see Brief Summary of full Prescribing Information on the adjacent page.

©2011 Dendreon Corporation. All rights reserved. March 2011. Printed in the U.S.A. Dendreon, the Dendreon logo, and PROVENGE are registered trademarks of Dendreon Corporation. P-A-03.11-026.00

www.PROVENGE.com

Stimulate a Response


Science & Technology Hall More to see, More to learn

Expand Your Educational Experience at AUA2011 – Visit the AUA Science & Technology Hall! The AUA’s Science & Technology Hall is a destination for every attendee at AUA 2011. Attend special events on the latest Innovation in the field of urology, take home valuable AUA Resources for your practice, participate in valuable hands-on Training and find out about the latest Technology available – Visit the AUA Science & Technology Hall for ...

Innovation

Training

Industry Clinical Update Theater, Booth 2141

Skills Enhancement Workshops, Hall C

Visit the Industry Clinical Update Theater for industry-supported presentations on the latest research, given by urology thought leaders. Refreshments are offered at most programs.

Train with the very best minds in urologic surgery, using the latest products, at our Skills Enhancement Workshops. Hands-on programs are offered throughout the day during exhibit hours.

Don’t forget to join us for breakfast! New morning programs offered beginning at 10 a.m. Sunday through Tuesday.

Resources

New Products Showcase, Booth 3337

Urology Resource Center, Booth 1819 Don’t leave AUA education behind at the meeting – visit the AUA Urology Resource Center to get Annual Meeting materials and valuable AUA resources on a USB flash drive that you can take with you; relax and network with your colleagues while you enjoy free WiFi and download the AUA2011 Mobile App! The complimentary USB flash drives will be loaded with AUA resources including Annual Meeting Posters, Course Handouts, Abstracts and links to AUA Guidelines, the Core Curriculum App, Patient Materials and more…be sure to stop by the AUA Urology Resource Center early as the USB flash drives are limited to the first 5,000 visitors!

American Urological ® Association, Inc.

American Urological

Technology Looking for what’s new in urology? The New Products Showcase features the latest advancements in select therapeutic areas – look for our “New Products Guide” for a list of products.

For a complete schedule of programs, check your Daily Schedule and your Pocket Planner, or consult the AUA2011 Mobile App.

Hall Hours SATURDAY, may 14: SUNDAY, MAY 15: MONDAY, MAY 16: TUESDAY, MAY 17:

11 a.m. - 6 p.m. 9 a.m. - 4 p.m. 9 a.m. - 4 p.m. 9 a.m. - 4 p.m.

www.AUA2011.org/HallSchedule


Registration Hours

Visit the CME Booth in Registration

Friday Noon – 6 p.m.

Sunday, May 15 Noon - 4 p.m.

Saturday

6:30 a.m. – 6 p.m.

Monday, May 16

6:30 a.m. - 4 p.m.

Sunday

6:30 a.m. – 4 p.m.

Tuesday, May 17

6:30 a.m. - 4 p.m.

Monday

6:30 a.m. – 4 p.m.

Wednesday, May 18

6:30 a.m. - 4 p.m.

Tuesday

6:30 a.m. – 4 p.m.

Thursday, May 19

6:30 a.m. - Noon

Wednesday

6:30 a.m. – 2 p.m.

Or visit www.AUAnet.org after May 20. All CME credit/participation must be claimed by December 31, 2011.

Educational Opportunities that Shouldn’t be Missed! Live Surgeries The 2011 Annual Meeting will feature two live surgeries, broadcast directly from the operating room. A didactic session—including tips and tricks from the expert panel—will follow each surgery. Saturday, May 14, 2011 8 a.m.-Noon: 001SP–Female Incontinence Procedures with Live Surgeries–Victor W. Nitti, MD, Course Director 1 – 5 p.m.: 005SP–Robot Assisted Radical Cystectomy and Extended Lymphadenectomy–Erik P. Castle, MD and John W. Davis, MD Tickets are $100 and can be purchased in AUA Registration.

AUA Forums Gain new perspectives and insights at the AUA Forums!

Forums are open to all Annual Meeting attendees and do not require registration.

Forum Schedule: Residents Forum – Getting Started: “A Blueprint for PostResidency Life” Saturday, May 14, 2011, 8:30 a.m. – 1:30 p.m., 207AB AUA and AACU Present the Urology Health Policy Forum Sunday, May 15, 2011, 10:30 a.m. – 12:30 p.m., 204BC Young Urologists Forum Monday, May 16, 2011, 12:15 – 1:45 p.m., 145AB Endocrine Forum Monday, May 16, 2011, 1 – 3:30 p.m., Ballroom B History of Urology Forum Monday, May 16, 2011, 1 – 5:30 p.m., Ballroom C

www.AUA2011.org

Late-Breaking Science Forum Tuesday, May 17, 2011, 1 – 3:30 p.m., 103AB AUA Foundation Research Forum “Showcasing Young Investigators” Monday, May 16, 2011, 3 – 5:30 p.m., 144ABC Global Perspectives in Urology Forum Topic: Male Incontinence and the Use of Prosthetics To Enhance Urinary Control

Wednesday, May 18, 2011, 1 – 2:30 p.m., 103AB

Hands-on Courses This year’s Annual Meeting offers more hands-on courses than ever before! Develop your skills under the direct guidance of experts in these three-hour interactive courses. These labs are among the most popular courses offered at the Annual Meeting—and seating is limited—so be sure to register early! Purchase tickets in Registration. 101HO: Prostate Ultrasound SOLD OUT 102HO: Ultrasound of Male Genitalia 103HO: Flexible Ureteroscopy for Renal Stones 104HO: Abdominal Ultrasound 105HO: Flexible Ureteroscopy for Renal Stones 106HO: Advanced Urologic Ultrasound 107HO: BPH Laser Therapy 108HO: Hands-on Course on Percutaneous Nephrostomy 109HO: Hands-on Course on Percutaneous Nephrostomy 110HO: Endourologia Practica: Tecnicas Quirurgicas Y Recomendaciones Practicas [Spanish Only] 111HO: Laparoendoscopic Single Site Surgery: Hands-On Skill Development 112HO: Ureteroscopy: Step-by-step 113HO: Hands-on Office Treatment of Male Sexual Dysfunction 114HO: Office Urodynamics 115HO: Laparoscopic Skills Training and Suturing 116HO: Surgical Approaches in Female Pelvic Surgery

   Schedule-at-a-Glance

1


2

plenary sessions — Hall D Sunday, May 15, 2011 7:30 – 7:35 a.m. Welcome and Introductions Datta G. Wagle, MD, President; Robert C. Flanigan, MD, Secretary 7:35 – 7:55 a.m. AUA Health Policy Washington Report­. Steven M. Schlossberg, MD, MBA 7:55 – 8:05 a.m. American Board of Urology Update. Timothy B. Boone, MD 8:05 – 8:25 a.m. Point-Counterpoint Physician Ownership of Ancillary Services are Good for Patients Moderator: David F. Penson, MD, MPH Debaters: Peter M. Knapp, Jr., MD (Pro); Brent K. Hollenbeck, MD (Con) 8:25 – 8:45 a.m. John Duckett Memorial Lecture Urology in 2040 – What Will It Look Like? Terry W. Hensle, MD 8:45 – 9:10 a.m. Panel Discussion Conflicting Guidelines for the Treatment of Vesicoureteral Reflux Moderator: Saul P. Greenfield, MD Panelists: Steven J. Skoog, MD; Julian Hsin-Cheng Wan, MD 9:10 – 9:30 a.m. State-of-the-Art Lecture Fetal Urologic Intervention Report Card: Valves, Myelomeningocele and Congenital Adrenal Hyperplasia. John W. Brock, III, MD 9:30 – 9:50 a.m. State-of-the-Art Lecture Urologic Malignancies in Children: Long-Term Implications for Adults. Michael L. Ritchey, MD 9:50 – 10 a.m. AUA Guideline Presentation Guidelines at the Crossroads. John B. Forrest, MD

10 – 10:20 a.m.

Point-Counterpoint

Semen Analysis—Is There a Definable Normal Range? Moderator: Stanton C. Honig, MD Debaters: Mark Sigman, MD (Numbers Are Important); Dolores J. Lamb, PhD (It’s Not Just About Numbers) 10:20 – 10:40 a.m. State-of-the-Art Lecture Male Reproduction as a Public Health Issue— Update on the CDC Working Group. Lawrence S. Ross, MD 10:40 – 11 a.m. Panel Discussion Challenges in the Treatment of Hypogonadism Within the Reproductive Years—Is it Safe? Moderator: Larry I. Lipshultz, MD Panelists: Natan C. Bar-Charma, MD; Edward D. Kim, MD; Mohit Khera, MD, MBA, MPH 11 – 11:20 a.m. State-of-the-Art Lecture Update on Sexually Transmitted Diseases. Daniel A. Shoskes, MD 11:20 – 11:40 a.m. News from Rising Stars A Review of the Last 30 Years of the AUA’s Research Scholars Program. Johannes Vieweg, MD (Obesity and Prostate Cancer) Stephen Freedland, MD 11:40 – Noon John K. Lattimer Lecture New Approaches to Cancer Immunotherapy. Steven A. Rosenberg, MD, PhD Noon Session Concludes

monday, may 16, 2011 Highlights from Saturday and Sunday Sessions

7:30 – 7:40 a.m. Sexual Function/Dysfunction. Trinity J. Bivalacqua, MD, PhD 7:40 – 7:50 a.m. BPH/LUTS. Lori B. Lerner, MD 7:50 – 8 a.m. Pediatric Urology. Carlos R. Estrada, Jr., MD 8 – 8:20 a.m. Point-Counterpoint The Management of Polycystic Kidneys in Renal Transplant Patients— Concomitant or Staged Nephrectomy? Moderator: Venkatesh Krishnamurthi, MD Debaters: Michael Phelan, MD (Concomitant); Patrick Luke, MD (Staged) 8:20 – 8:50 a.m. Panel Discussion Antimicrobial Prophylaxis for Genitourinary Prosthetics Moderator: Chirpriya B. Dhabuwala, MD Panelists: Culley C. Carson, III, MD; Lawrence S. Hakim, MD

8:50 – 9:20 a.m. Panel Discussion Recurrent UTIs in the Female Moderator: Toby C. Chai, MD Panelists: Robert M. Moldwin, MD (Modern Strategies for Prevention of Recurrent UTIs); Stephen R. Kraus, MD (Recurrent UTIs in Neurogenic Bladder Patients); Joseph C. Liao, MD (What’s New in the Diagnosis of UTIs) 9:20 – 9:50 a.m. Panel Discussion Controversies in Urethral Reconstruction Moderator: Steven B. Brandes, MD Panelists: Sanjay B. Kulkarni, MD; Guido Barbagli, MD; Allen F. Morey, MD 9:50 – 10:05 a.m. State-of-the-Art Lecture New and Emerging Concepts in Neuromodulation. Kenneth M. Peters, MD

Schedule-at-a-Glance

www. AUA2011.org  


10:05 – 10:25 a.m. Point-Counterpoint Single Incision Sling—Is it Ready for Prime Time? Moderator: Sender Herschorn, MD Debaters: Michael J. Kennelly, MD (Pro); Alexander Gomelsky, MD (Con) 10:25 – 10:55 a.m. Panel Discussion Office-Based Management of SUI in 2011 Moderator: Gary E. Lemack, MD Panelists: Saad Juma, MD (Radio Frequency Ablation); Deborah J. Lightner, MD (Pessaries, Plugs and Barrier Devices); Richard D. Cespedes, MD (Injectables) 10:55 – 11:10 a.m. State-of-the-Art Lecture What is on the Horizon in Drug Therapy for OAB? Karl-Erik Andersson, MD, PhD

11:10 – 11:25 a.m. State-of-the-Art Lecture How Do I Manage a Failed Mid-Urethral Sling? Eric S. Rovner, MD 11:25 – 11:40 a.m. State-of-the-Art Lecture Association of Metabolic Syndrome, Coronary Artery Disease and Kidney Stone Formation Dean G. Assimos, MD 11:40 – Noon Point-Counterpoint Endorectal MRI for the Preoperative Staging of Prostate Cancer Moderator: James A. Eastham, MD Debaters: Ashutosh K.Tewari, MD (Pro); Joseph A. Smith, Jr. MD (Con) Noon Session Concludes

tuesday, may 17, 2011 Highlights from Monday Sessions

7:30 – 7:40 a.m. Endourology. Jorge Gutierrez-Aceves, MD 7:40 – 7:50 a.m. Infection and Inflammation. Richard E. Berger, MD 7:50 – 8 a.m. Urodynamics and Female Urology. Anurag D. Das, MD 8 – 8:10 a.m. Late Breaking News Pelvic Injuries: The Military Experience. James R. Jezior, MD 8:10 – 8:30 a.m. The Société Internationale d’Urologie (SIU) Lecture

Fistula in Sub-Saharan Africa. Dirk J.M.K. DeRidder, MD 8:30 – 8:50 a.m. State-of-the-Art Lecture What is New in PSA-Based Screening for Prostate Cancer—An Update of the ERSPC Study. Fritz H. Schroder, MD 8:50 – 9:10 a.m. State-of-the-Art Lecture Personalized Medicine in Bladder Cancer. Daniel Theodorescu, MD, PhD 9:10 – 9:30 a.m. State-of-the-Art Lecture Imaging & the Treatment of Nodal Disease in Bladder and Prostate Cancer. Urs E. Studer, MD 9:30 – 10 a.m. Panel Discussion Novel Techniques in Partial NephrectomyCase Discussions. Moderator: John A. Libertino MD Panelists: Inderbir S. Gill, MD, MCh (Hypotensive Robotic Technique); Louis R. Kavoussi, MD (Non-Clamp Technique) 10 – 10:10 a.m. Late Breaking News The VA/NCI/AHRQ CSP#407: Prostate Cancer Intervention Versus Observation Trial (PIVOT): Main Results From a Randomized Trial Comparing Radical Prostatectomy to Watchful Waiting in Men with Clinically Localized Prostate Cancer. Timothy J.Wilt, MD, MPH

www.AUA2011.org

10:10 – 10:30 a.m. State-of-the-Art Lecture Risks of Imaging and Monitoring Patients with Urologic Cancers. Brian Herts, MD 10:30 – 10:40 a.m. Late Breaking News Denosumab to Prevent Bone Metastases (Dmab 147 Study) Matthew R. Smith, MD, PhD 10:40 – 11 a.m. The European Association of Urology (EAU) Lecture

Challenging Dogma: Current Role of Endourology and Renal Preservation In Upper Tract TCC Management. Anup Patel, MD 11 – 11:20 a.m. State-of-the-Art Lecture Prostate Cancer Susceptibility Genes. Kathleen A. Cooney, MD, FACP 11:20 – 11:30 a.m. Late Breaking News Response of Human Kidney to Ischemia During Partial Nephrectomy: Results from a Prospective Clinical Trial. Dipen J. Parekh, MD 11:30 – 11:40 a.m. Late Breaking News A Prospective Trial Comparing Photoselective Vaporization of the Prostate (PVP-120) to Transurethral Resection of the Prostate. J. Paul Whelan, MD 11:40 – Noon Urological Association of Asia (UAA) Lecture From an Academic Urologist to a Health Policy Maker—What You Need to Know. Allen Wen-Hsiang Chiu, MD Noon Session Concludes

   Schedule-at-a-Glance

3


4

wednesday, may 18, 2011 Highlights from Tuesday Sessions

Bladder/Kidney Cancer. Curtis A. Pettaway, MD Prostate Cancer. Thomas J. Guzzo, MD, MPH Basic Research. David F. Jarrard, MD Critical Discussion Sexual Health in Elderly Men and Women Presenters: Lindsey A. Kerr, MD (Women’s Sexual Health, Sexual Response); Allen D. Seftel, MD (Men’s Sexual Health, Markers for CV Disease, Urinary Control) Discussant: Tomas L. Griebling, MD, MPH 8:25 – 8:45 a.m. Panel Discussion Care of the Aging Male—Should Urology Be the “Medical Home?” Moderator: Ananias C. Diokno, MD Panelists: Kevin Pranikoff, MD; Paul Misch, MD 8:45 – 9:05 a.m. State-of-the-Art Lecture CROES Global Study on PCNL. Jean de la Rosette, MD 9:05 – 9:30 a.m. Panel Discussion Simulation in Surgical Training in Urology Moderator: Elspeth M. McDougall, MD Panelists: Robert M. Sweet, MD; Matthew T. Gettman, MD; Pilar M. Laguna Pes, MD 9:30 – 9:40 a.m. State-of-the-Art Lecture AUA Recommendations for Robotic Surgery Credentialing. Chandru P. Sundaram, MD 9:40 – 10:05 a.m. Panel Discussion Radical Prostatectomy—Open vs. Robotic vs. Laparoscopic 7:30 – 7:40 a.m. 7:40 – 7:50 a.m. 7:50 – 8 a.m. 8 – 8:25 a.m.

Moderator: Ralph V. Clayman, MD Panelists: Joel B. Nelson, MD (Open); Jens Rassweiler, MD (Laparoscopic); Mani Menon, MD (Robotic) 10:05 – 10:25 a.m. Point-Counterpoint More or LESS Moderator: Paul Van Cangh, MD Debaters: J. Stuart Wolf, MD (Standard Laparoscopy); Mihir M. Desai, MD (LESS) 10:25 – 10:45 a.m. Presidential Address AUA: Relevance, Progress, Commitment Datta G.Wagle, MD 10:45 – 11:05 a.m. Ramon Guiteras Lecture Early Diagnosis of Prostate Cancer Through PSA Testing Saves Lives. William J. Catalona, MD 11:05 – 11:30 a.m. Panel Discussion Difficult Endourologic Problems Moderator: James E. Lingeman, MD Panelists: Mantu Gupta, MD; John D. Denstedt, MD; Mahesh R. Desai, MD Panel Discussion 11:30 – Noon The Fantastic Voyage: Advances in Robotic Surgery Moderator: Steven Y. Nakada, MD Panelists: S. Duke Herrell, III, MD (Robotic Image-Guided Therapy); Ashok K. Hemal, MD (Robotic Platform and Equipment Horizon); Benjamin R. Lee, MD (Remote Robotic Surgery) Noon Session Concludes

thursday, may 19, 2011 Take-Home Messages

7:30 a.m. 7:40 a.m. 7:50 a.m. 8 a.m. 8:10 a.m. 8:20 a.m. 8:30 a.m. 8:40 a.m. 8:50 a.m. 9 a.m. 9:10 a.m. 9:20 a.m. 9:30 a.m.

Localized Prostate Cancer. E. David Crawford, MD Advanced Prostate Cancer. Maha Hussain, MD Pediatric Urology. John M. Park, MD Infection. Miguel Srougi, MD Infertility. Moshe Wald, MD Basic Science. Zhou Wang, PhD Stone Disease. Manoj Monga, MD Transplantation/Vascular Surgery. Puneet Sindhwani, MD Penile and Urethral Cancer. Li Ping Xie, MD Testis Cancer. Stephen D. Beck, MD Trauma/Reconstructive Surgery. Christopher D. McClung, MD Sexual Function/Dysfunction. Gerald B. Brock, MD Robotic Surgery. Vipul R. Patel, MD

9:40 a.m. 9:50 a.m. 10 a.m. 10:10 a.m. 10:20 a.m. 10:30 a.m. 10:40 a.m. 10:50 a.m. 11 a.m. 11:10 a.m. 11:20 a.m. 11:30 a.m. 11:40 a.m. 11:50 a.m. Noon

Schedule-at-a-Glance

Female Urology/Incontinence. Paulo C.R. Palma, MD Urodynamics. Mayank M. Agarwal, MD BPH/LUTS. Jaspreet S. Sandhu, MD Laparoscopic Technology. Monish Aron, MD Laparoscopic Oncology. Alexandre Mottrie, MD Endourology. Joel M. H.Teichman MD Outcomes Analysis. Jim C. Hu, MD Kidney Cancer. Samir Taneja, MD Bladder Cancer. Arturo Mendoza-Valdes, MD Urinary Diversion. Anil Mandhani, MD Uroradiology. Ardeshir R. Rastinehad, MD Uro-pathology. Guliz A. Barkan, MD Office Management/Practice. James A. Sylora, MD Health Policy. Danil Makarov, MD Session Concludes

www. AUA2011.org  


5

to this extraordinary event!

AUA WELCOMING RECEPTION AT AUA2011 National Air & Space Museum May 15, 2011 7:30 pm Tickets are $95 Visit the Welcoming Reception Ticket Booth in Registration. www.AUA2011.org

   Schedule-at-a-Glance


6

Easy to Download and Free! Sessions Maps Abstracts Speakers Daily News My Schedule Networking Exhibitors Industry Programs

For iPhone, iTouch and iPad users: From your handheld device, go to the iTunes App Store and search for “AUA Annual Meeting” to locate the app. Click on the “free” button, which will take you to the install screen. Next, download the AUA Annual Meeting App as you would any other application from the iTunes App Store. It’s that easy!

For BlackBerry, Android and all other Webenabled smartphones: Point your mobile phone’s web browser to m.core-apps.com/TriStar-AUA11. On this web-based mobile site, you will be directed to the proper download version for your device type.

Need help? Visit the AUA Resource Center (Booth 1819 in the Science & Technology Hall) for assistance. Mobile app brought to you by Schedule-at-a-Glance

www. AUA2011.org  


ALL SESSIONS HELD IN WALTER E. WASHINGTON CONVENTION CENTER UNLESS OTHERWISE NOTED.

Schedule - at - a - glance Friday - MORNING & AFTERNOON Courses Events

7 a.m. 8 a.m. 9 a.m. 10 a.m. 11 a.m. Noon 1 p.m. 2 p.m. 3 p.m.

4 p.m.

5 p.m.

7

6 p.m.

7 p.m.

8 a.m. – 5:30 p.m. Practice Management Conference, 146BC 7 a.m. – 4:15 p.m. Hands-On Ultrasound, 152A 4:30 – 7 p.m.

Symposia

1 – 6:30 p.m.

Specialty Societies

8 a.m. – 1 p.m. Society of University Urologists (SUU) Salon C by Main Registration

Basic Science Symposium, 143ABC

1 – 5 p.m.

The PULSE™ Symposium Personalization of Care for CastrationResistant Prostate Cancer and the Evolving Role of Immunotherapy, 103AB

6:30 – 9 p.m. Re-Evaluating Your Practice: Managing Skeletal-Related Events in Patients with Prostate Cancer, 147AB

Society for Fetal Urology, Grand Hyatt, Constitution AB

1 – 5:30 p.m.

Society of Urology Chairpersons and Program Directors (SUCPD) Salon C

Visit the AUA Products Store for the latest educational resources and products! Science & Technology Hall – Booth 3413

New! 2011 Surgical Video Library Box Set Now, you can add all the 2011 Annual Meeting Videos to your collection! Complete box set includes 10 DVD sessions—more than 120 surgical videos and 20 hours of video! Special Package Price $149.00 for the complete set of DVDs.

And much more! Stop by Booth 3413 www.AUA2011.org

   Schedule-at-a-Glance


saturday - MORNING 6 a.m.

6:30 a.m.

ALL SESSIONS HELD IN WALTER E. WASHINGTON CONVENTION CENTER

7 a.m.

7:30 a.m.

8 a.m.

8:30 a.m.

9 a.m.

101HO Prostate Ultrasound, 152A HANDS ON 8 a.m. – Noon 001SP Female Incontinence Procedures 9 a.m. – Noon

Science & Video Forums Technology Hall Sessions

Courses

7 – 10 a.m.

8:30 a.m. – 1:30 p.m. Residents

7:30 – 10 a.m. Heart of the Matter: Hypogonadism Management with Testosterone Therapy, E Salon C

Satellite Symposia

7:30 – 10 a.m. Reason for Hope: Key Advances in the Management of Castration-Resistant Prostate Cancer, 150AB

6:45 a.m. – 5 p.m.

Specialty Societies/ International Programs

8

Engineering and Urology Society, Grand Hyatt, Constitution AB 7:30 a.m. – 5 p.m. Society for Pediatric Urology (SPU), Renaissance DC, Grand 7:50 a.m. – 12:30 p.m. Arab Association of Urology 8 a.m. – Noon SBUR / SUO (Joint Session), Grand Hyatt, 8 a.m. – 1 p.m. World Chinese Urological Society, 209ABC 8:30 a.m. – 4 p.m. Indian American 8 a.m. – 4 p.m. AUA/Confederacion Americana de Urologia (CAU),

Schedule-at-a-Glance

www. AUA2011.org  


UNLESS OTHERWISE NOTED. 9:30 a.m.

10 a.m.

10:30 a.m.

11 a.m.

11:30 a.m.

Noon

with Live Surgeries, Ballroom A 103HO Flexible Ureteroscopy for Renal Stones, 152B HANDS ON 10 a.m. – Noon 002IC Nutrition Counseling for the Prevention of Urolithiasis, 143ABC 061IC Peyronie’s Disease and Priapism: Current Understanding of Pathophysiology and Review of Medical and Surgical Therapy, 151AB 10 a.m. – 1 p.m. 102HO Ultrasound of Male Genitalia, 152A HANDS ON

10:30 a.m. – Noon Award Winning Video Sessions, 209ABC

Forum, 207AB 11 a.m. – 6 p.m. Science & Technology Hall Open 11 a.m. – 6 p.m. Skills Enhancement Workshops, Booths 217, 417, 425 Noon – 5:30 p.m. ICU Theater, Booth 2141

North/Central

(AAU), 204BC Independence A Urological Assoc. (IAUA), Marriott Metro Center, Grand Ballroom Ballroom B & C

Noon – 4 p.m. Society for Urodynamics and Female Urology (SUFU), Renaissance DC, East West

www.AUA2011.org

   Schedule-at-a-Glance

9


saturday - afternoon 12:30 p.m.

1 p.m.

2 p.m.

3 p.m.

2:30 p.m.

3:30 p.m.

1 – 4 p.m. 1 – 5 p.m.

104HO Abdominal Ultrasound, 152A HANDS ON 005SP Robot-Assisted Radical Cystectomy with Extended Lymphadenectomy, Ballroom A 2 – 5 p.m. 105HO Flexible Ureteroscopy for Renal Stones, 152B HANDS ON 3:15 – 6:30 p.m. 006PG 007PG

Podium Sessions

1 – 3 p.m. POD01 Adrenal: Surgery/Tumors/Benign & Malignant Disease, 209ABC POD02 General & Epidemiological Trends & Socioeconomics: Evidence-Based Medicine & Outcomes, 101

1 – 3 p.m.

Poster Sessions Forums

1:30 p.m.

ALL SESSIONS HELD IN WALTER E. WASHINGTON CONVENTION

1 – 3 p.m. 003IC Practical Considerations in Genitourinary Prosthetic Surgery, 151AB 004IC Social Media Marketing: What You Need to Know About Facebook, Twitter, YouTube and Blogging to Market Your Urologic Practice, 143ABC

Courses

10 a.m. – 1 p.m. 102HO Ultrasound of Male Genitalia, 152A

3:30 – 5:30 p.m.

MP01 Trauma/Reconstruction: Trauma & Reconstructive Surgery, 201

8:30 a.m. – 1:30 p.m. Residents Forum, 207AB

1:30 p.m. – 2:30 p.m. Endo Pharmaceuticals, ICU

Theater, Booth 2141

11:00 a.m. – 6 p.m. Skills Enhancement Workshops, Booths 217, 417, 425

Satellite Symposia

Science & Technology Hall

11 a.m. – 6 p.m. Science & Technology Hall Open

Specialty Soc./ Int’l Prog.

10

Noon – 4 p.m.

Society for Urodynamics and Female Urology (SUFU), Renaissance DC, East West

12:30 – 5 p.m. Society of Urologic Oncology (SUO), Grand Hyatt, Independence A 1:30 – 3:30 p.m. Society for Basic Urologic Research (SBUR), Grand Hyatt, Lafayette Park

Schedule-at-a-Glance

www. AUA2011.org  


CENTER UNLESS OTHERWISE NOTED. 4 p.m.

4:30 p.m.

11 5 p.m.

5:30 p.m.

6 p.m.

6:30 p.m.

Chronic Kidney Disease (CKD): How to Preserve and Maintain Optimal Renal Function, 151AB Urologic Diseases for the Allied Health Professional, 143ABC 4 – 7 p.m. 106HO Advanced Urologic Ultrasound, 152A HANDS ON

MP02 General & Epidemiological Trends & Socioeconomics: Evidence-Based Medicine & Outcomes, 201 MP03 General & Epidemiological Trends & Socioeconomics: Practice Patterns, Cost Effectiveness, 209ABC MP04 Trauma/Reconstruction: Trauma & Reconstructive Surgery, 202A

4:30 – 5:30 p.m. Ethicon Endo-Surgery, ICU

Theater, Booth 2141

4 – 6 p.m.

Saturday Social

6:30 – 8:30 p.m. Refractory Idiopathic and Neurogenic Detrusor Overactivity: Case Studies of Localized Treatment Modalities, E Salon C

www.AUA2011.org

   Schedule-at-a-Glance


sunday - Morning 6 a.m.

6:30 a.m.

ALL SESSIONS HELD IN WALTER E. WASHINGTON CONVENTION CENTER UNLESS

7 a.m.

7:30 a.m.

8:30 a.m.

8 a.m.

9 a.m.

Plenary Sessions

7:30 – Noon Hall D

Courses

6 – 8 a.m. 008IC BPH Medical Management, 151AB 009IC Management of Castration Resistant Prostate Cancer, 146ABC 010IC The Role of Sacral Neuromodulation in Urologic Practice, 150AB 011IC Accreditation, Establishment and Management of Office-Based Urologic Surgery, 147AB 012IC Medical Management of Metastatic Renal Cell Carcinoma: How to Do It, by Urologists for Urologists, 143ABC 7 – 10 a.m.

107HO BPH Laser Therapy, 152A HANDS ON 108HO Hands-On Course on Percutaneous Nephrostomy, 152B HANDS ON 8:30 – 11:45 a.m.

POD03 Prostate Cancer: Staging, 103 POD04 Trauma/Reconstruction: Trauma & Reconstructive

8 – 10 a.m.

MP05 MP06 MP07 MP08

Kidney Cancer: Basic Research, 202A Prostate Cancer: Basic Research, 202B Prostate Cancer: Epidemiology and Natural History, Stem Cell Research, 207A

Podium Sessions Forums

Video Sessions

Poster Sessions

013PG 014PG 015PG 016PG 017PG 018PG 019PG

8 – 10 a.m.

9 a.m. – 4 p.m.

Science & Technology Hall Specialty Societies

12

9 a.m. – 4 p.m. 6:30 – 9:30 a.m. Society of Women in Urology (SWIU), Renaissance DC, West AB

Schedule-at-a-Glance

8 a.m. – 12:30 p.m. Sexual Medicine Society of North

www. AUA2011.org  


OTHERWISE NOTED. 9:30 a.m.

10 a.m.

10:30 a.m.

11 a.m.

11:30 a.m.

Noon

Lunch & Learn Sessions Sunday’s Topic: Case Discussions in Prostate Cancer Noon - 1:30 p.m. – Science & Technology Hall Booth #3951 Limited seating! Tickets are $75 and can be purchased in Registration. Featured Experts for Sunday’s Lunch and Learn

Gerald L. Andriole, Jr., MD SOLD OUT Peter T. Scardino, MD SOLD OUT Robert P. Myers, MD SOLD OUT Judd W. Moul, MD SOLD OUT Laurence H. Klotz, MD SOLD OUT William J. Catalona, MD SOLD OUT Eric A. Klein, MD Nelson N. Stone, MD Michael S. Cookson, MD Ian M. Thompson, Jr., MD

Basics and Advances in Pediatric Robotic Urology, 151AB How to Perform Extraperitoneal Laparoscopic and Robotic Surgery, 146ABC Radical Retropubic Prostatectomy, 150AB Management of Non-Muscle-Invasive Bladder Cancer: Practical Solutions for Common Problems, 144ABC Rehabilitation of Neurogenic Bladder Function, 147AB Pelvic Pain Syndromes: Practical and Multidisciplinary Approaches to Diagnoses and Management, 143ABC Urolithiasis: Metabolic Evaluation and Medical Treatment, 145AB 10:30 a.m. – 1:30 p.m.

109HO

Hands-On Course on Percutaneous Nephrostomy, 152B

10:30 a.m. – 12:30 p.m. POD05 General & Epidemiological Trends & Socioeconomics: Practice Patterns, Cost Effectiveness, 102 POD06 Pediatrics: Andrology - Cryptorchidism & Varicoceles, 209ABC POD07 Prostate Cancer: Epidemiology and Natural History, 103 POD08 Prostate Cancer: Localized, 202A POD09 Urothelial Cancer: Markers + Natural History & Pathophysiology, 101

Surgery, 102

10:30 a.m. – 12:30 p.m. MP09 Bladder and Urethra: Anatomy, Physiology and Pharmacology, 207B MP10 Kidney Cancer: Basic Research, 207A MP11 Pediatrics: Basic Research, 202B MP12 Prostate Cancer: Basic Research, 206 MP13 Prostate Cancer: Staging, 201

206

10:30 a.m. – 12:30 p.m.

Male Voiding Dysfunction (BPH & Incontinence), Oncology and Prostate Cancer, Ballroom A

10:30 a.m. – 12:30 p.m. AUA and AACU present the Urology Health Policy Forum, 204BC

Science & Technology Hall Open 10 – 11 a.m. Beckman Coulter, ICU Theater,

Booth 2141

Noon – 1 p.m. Lilly USA, LLC, ICU

Theater, Booth 2141

Skills Enhancement Workshops, Booths 217, 417, 425

America (SMSNA), Renaissance DC, Grand North and Central

www.AUA2011.org

   Schedule-at-a-Glance

13


sunday - afternoon 12:30 p.m.

1 p.m.

1:30 p.m.

ALL SESSIONS HELD IN WALTER E. WASHINGTON CONVENTION CENTER 2 p.m.

3 p.m.

2:30 p.m.

3:30 p.m.

10:30 a.m. – 1:30 p.m. 109HO Hands-On Course on Percutaneous Nephrostomy, 152B HANDS ON

Courses

1 – 3 p.m. 020IC Risk-Adapted Treatment and Prevention of Non-Muscle-Invasive Bladder Cancer, 151AB 021IC Female Urology: Controversies and Consensus: A Case-Based Approach, 146ABC 022IC Office-Based Urologic Surgery, 150AB 023IC Effective Training and Utilization of Allied Health Professionals in Urology, 147AB 024IC Nocturia: Advances in Diagnosis and Management, 143ABC 025IC Holmium Laser Applications for Surgical Management of BPH, 145AB (Translated in Spanish) 2 – 5 p.m. 110HO Endourology—Surgical Techniques and Practical Hints 111HO Laparoendoscopic Single-Site Surgery (LESS): Hands-on Skill

3:30 – 5:30 p.m. 1 – 3 p.m POD10 Bladder and Urethra: Anatomy, Physiology and Pharmacology, 209ABC POD11 General & Epidemiological Trends & Socioeconomics: Practice Patterns, Cost Effectiveness, 102 POD12 Pediatrics: Congenital Anomalies – Kidney & Ureter, 101 POD13 Prostate Cancer: Epidemiology and Natural History, 103 POD14 Prostate Cancer: Localized, 201 POD15 Urothelial Cancer: Medical & Surgical Therapy, 202A

3:30 – 5:30 p.m.

Podium Sessions

Science & Video Forums Technology Hall Sessions

Poster Sessions

3:30 – 5:30 p.m.

Specialty Soc./ Int’l Prog.

14

1 – 3 p.m. MP14 Kidney Cancer: Basic Research, 207B MP15 Prostate Cancer: Basic Research, 206

1 – 3 p.m. Transplantation, Urolithiasis and Hydronephrosis, Ballroom A

3:30 – 5:30 p.m.

3 – 5:30 p.m. 9 a.m. – 4 p.m.

AUA Foundation Research

Science & Technology Hall Open – Skills Enhancement Workshops, Booths 217, 417, 425 1:30 – 2:30 p.m. Pfizer Inc., ICU Theater,

Noon – 1 p.m. Lilly USA, LLC, ICU

Booth 2141

3 – 4 p.m. Abbott Laboratories, ICU Theater,

Booth 2141

Theater, Booth 2141

Noon – 1:30 p.m.

Lunch & Learn

12:45 p.m. – 4:30 p.m. 1 – 5 p.m. 1 – 5:15 p.m. 1 – 5:30 p.m.

Society of Urologic Robotic Surgery (SURS), Grand Hyatt, Constitution CDE 3 – 6 p.m. R. Frank Jones Urological  Society for Infection & Inflammation in Urology (SIIU), Grand Hyatt, Independence H  Society of Genitourinary Reconstructive Surgeons (GURS), Grand Hyatt, Independence A 3:30 – 5:30 p.m.  Geriatric Urological Society (GUS), Grand Hyatt, Lafayette Park 2 – 6 p.m. Japanese Urological Association (JUA), Renaissance DC, West AB 3 – 6:20 p.m. Korean World Urologic Congress,

Schedule-at-a-Glance

www. AUA2011.org  


UNLESS OTHERWISE NOTED. 4 p.m.

4:30 p.m.

5 p.m.

Presentado en español, 152A HANDS ON Development, 152B HANDS ON

026IC Prostate Cancer Diagnostics: PSA, Prostate Biopsy and Beyond, 151AB 027IC Incontinence in Women: An Objective Look at the Options, 146ABC 028IC Male Health, 150AB 029IC Robotic Radical Cystectomy: Getting Started, and Tips and Tricks from the Experts, 147AB 030IC Botulinum Toxin: Why Use It, How To Do It, What Are the Results? 143ABC 031IC Urolithiasis: Surgical Management, Percutaneous, Shock Wave Lithotripsy and Ureteroscopy, 145AB (Translated in Spanish)

POD16 POD17 POD18 POD19 MP16 MP17 MP18 MP19 MP20 MP21

5:30 p.m.

6 p.m.

6:30 p.m.

AUA Welcoming Reception Tonight! 7:30 p.m. See pg. 1 for details.

to this extraordinary event!

General & Epidemiological Trends & Socioeconomics: Quality of Life, 101 Prostate Cancer: Advanced, 103 Prostate Cancer: Localized, 102 Urothelial Cancer: Upper Tract Tumors, 209ABC

Bladder Cancer: Basic Research, 202A Kidney Cancer: Evaluation and Staging, 207B Pediatrics: Congenital Anomalies – Lower Urinary Tract & Genitalia, 207A Pediatrics: Imaging/Infections & Vesicoureteral Reflux, 201 Penis/Testis/Urethra: Benign & Malignant Disease, 202B Prostate Cancer: Basic Research, 206

Female Voiding Dysfunction (Pelvic Reconstruction and Incontinence), Ballroom A

Forum, 144ABC

Society, Renaissance DC, Renaissance East Association Francaise d’Urologie, Grand Hyatt, Independence Ballroom BE Grand Hyatt, Constitution AB

www.AUA2011.org

   Schedule-at-a-Glance

15


monday - morning 6 a.m.

7 a.m.

7:30 a.m.

8 a.m.

8:30 a.m.

9 a.m.

Plenary Sessions

7:30 – Noon Hall D

6 – 8 a.m. 032IC 033IC 034IC 035IC 036IC

Debates on Controversial Issues in Prostate Cancer: From Screening to Prevention and Treatment, 146ABC Pelvic Pain: Common Causes and Practical Solutions, 150AB Radiation Exposure: How to Protect Patients and Personnel, 144ABC Surgical and Minimally Invasive Management of Female Stress Urinary Incontinence: Which Procedure for Which Patient? 147AB Male Infertility/Hypogonadism for the Allied Health Professional, 143ABC 7 – 10 a.m. 112HO Ureteroscopy: Step-by-Step, 152A HANDS ON 113HO Hands-on Office Treatment of Male Sexual Dysfunction, 152B HANDS ON 8:30 – 11:45 a.m. 037PG 038PG 039PG 040PG 041PG 042PG 043PG

8 – 10 a.m. POD20 Infections/Inflammation of the Genitourinary Tract: POD21 Pediatrics: Bladder Dysfunction - Myelodysplasia, Enuresis, 209ABC POD22 Penis/Testis/Urethra: Benign & Malignant Disease, POD23 Prostate Cancer: Detection and Screening, 103

Poster Sessions

8 – 10 a.m.

Video Sessions

Podium Sessions

Courses

6:30 a.m.

ALL SESSIONS HELD IN WALTER E. WASHINGTON CONVENTION CENTER UNLESS

MP22 Kidney Cancer: Evaluation and Staging, 206 MP23 Prostate Cancer: Advanced, 202B MP24 Prostate Cancer: Basic Research, 207A MP25 Sexual Function/Dysfunction/Andrology: Basic MP26 Technology & Instruments: Robotics/Laparoscopy, MP27 Urodynamics/Incontinence/Female Urology:

Science & Technology Hall

Forums

8 – 10 a.m. Reconstruction Transitional Cell Carcinoma and Adrenal, Ballroom A

9 a.m. – 4 p.m.

9 a.m. – 4 p.m.

Specialty Soc./ Int’l Prog.

16

Schedule-at-a-Glance

www. AUA2011.org  


OTHERWISE NOTED. 9:30 a.m.

10 a.m.

10:30 a.m.

11 a.m.

11:30 a.m.

Noon

Lunch & Learn Sessions Monday’s Topic: Case Discussions in Voiding Dysfunction/Female Urology/BPH Noon - 1:30 p.m. Science & Technology Hall, #3951 Limited seating! Tickets are $75 and can be purchased in Registration. Featured Experts for Monday’s Lunch and Learn

Renal Mass Biology, Relevant Anatomy, Treatment Algorithms (Observation vs. Ablation vs. Extirpation): A Case-Oriented Seminar, 151AB Electronic Health Records for Urologists: A Selection and Implementation, 146ABC Primary and Reoperative Hypospadias Repair: Evidence-Based Decision Making, 150AB The Infertile Male: Evaluation, Advanced Testing, Surgery and ART, 144ABC Advanced Robotic Urologic Oncology: A Video-Based Analysis, 147AB Complications of Incontinence and Prolapse Surgery: Evaluation, Intervention and Resolution: A Review from Both Specialties, 143ABC Practical Uroradiology: The Office-Based Interpretation of Urologic Radiographic Studies, 145AB 10:30 a.m. – 1:30 p.m.

114HO

David R. Staskin, MD Eric S. Rovner, MD J. Christian Winters, MD Shlomo Raz, MD SOLD OUT Roger R. Dmochowski, MD Jeffrey Weiss, MD Michael B. Chancellor, MD Raymond R. Rackley, MD Gary E. Lemack, MD Christopher R. Chapple, MD SOLD OUT

Office Urodynamics, 152B HANDS ON

10:30 a.m. – 12:30 p.m. POD24 Infections/Inflammation of the Genitourinary Tract: Interstitial Cystitis, 102 POD25 Kidney Cancer: Evaluation and Staging, 209ABC POD26 Penis/Testis/Urethra: Benign & Malignant Disease, 103 POD27 Prostate Cancer: Detection and Screening, 101 POD28 Prostate Cancer: Localized, 202A POD29 Urodynamics/Incontinence/Female Urology: Incontinence: Evaluation & Therapy, 207A

Interstitial Cystitis, 101 Voiding Dysfunction, 102

10:30 a.m. – 12:30 p.m. MP28 Bladder Cancer: Basic Research, 207B MP29 Prostate Cancer: Advanced, 201 MP30 Sexual Function/Dysfunction/Andrology: Basic Research, 206 MP31 Technology & Instruments: Robotics/Laparoscopy, 202B

Research, 202A 201

Basic Research, 207B

10:30 a.m. – 12:30 p.m. Kidney & Ureter Oncology Ballroom A

12:15 – 1:45 p.m. Young Urologists Forum, 145AB Science & Technology Hall Open 10 – 11 a.m. Centocor Ortho-Biotech, Inc., ICU Theater, Booth 2141

Noon – 1 p.m. Watson Pharmaceuticals, ICU Theater, Booth 2141

Skills Enhancement Workshops, Booths 217, 417, 425

www.AUA2011.org

   Schedule-at-a-Glance

17


monday - afternoon 12:30 p.m.

Noon – 4 p.m.

1 p.m.

1:30 p.m.

ALL SESSIONS HELD IN WALTER E. WASHINGTON CONVENTION CENTER 2 p.m.

3 p.m.

2:30 p.m.

3:30 p.m.

115HO Laparoscopic Skills Training and Suturing, Hall E, Lab #2 HANDS ON 1 – 3 p.m. 044IC Clinical Care Pathways to Optimize Patient Outcomes in Urologic Surgery, 151AB 045IC Difficult Cases in High-Risk Bladder Cancer: An Evidence-Based Approach, 146ABC 046IC Testicular Cancer: Current Concepts and Controversies, 150AB 047IC Pay-for-Performance: A Survival Guide for Urologists,144ABC 048IC Clinical Research for the Practicing Urologist, 147AB 049IC UTIs: New Management Guidelines and Current Controversies, 143ABC

Courses

2 – 5 p.m.

Podium Sessions

1 – 3 p.m.

Poster Sessions Science & Video Forums Technology Hall Sessions

116HO Surgical Approaches in Female Pelvic Surgery, 152B HANDS ON 3:15 – 6:30 p.m.

1 – 3 p.m.

Specialty Soc./ Int’l Prog.

18

POD30 POD31 POD32 POD33

Infections/Inflammation of the Genitourinary Tract: Kidney & Bladder, 209ABC Pediatrics: Reconstructive Surgery, 102 Prostate Cancer: Detection and Screening, 101 Technology & Instruments: Robotics/Laparoscopy, 103

3:30 – 5:30 p.m.

3:30 – 5:30 p.m.

MP32 Bladder Cancer: Basic Research, 207B MP33 Kidney Cancer: Localized, 201 MP34 Prostate Cancer: Localized, 202A MP35 Sexual Function/Dysfunction/Andrology: Basic Research, 206 MP36 Urinary Diversion: Bladder Reconstruction, Augmentation,Substitution, Diversion, 202B MP37 Urodynamics/Incontinence/Female Urology: Incontinence – Evaluation & Therapy, 207A

1 – 3 p.m. Prostate Oncology Ballroom A

12:15 – 1:45 p.m. Young Urologists Forum, 145AB 1 – 3:30 p.m. Endocrine Forum Ballroom B 1 – 5:30 p.m. History of Urology Forum Ballroom C 9 a.m. – 4 p.m. Science & Technology Hall Open – Skills Enhancement Workshops, Booths 217, 417, 425 Noon – 1 p.m. 1:30 – 2:30 p.m. Watson Pharmaceuticals, Amgen, ICU Theater, Booth 2141 ICU Theater,

3 – 4 p.m. Caris Life Sciences, ICU Theater,

Booth 2141

Booth 2141

Noon – 1:30 p.m. Lunch & Learn 1 – 5 p.m.

Research on Calculus Kinetics Society (R.O.C.K.), Renaissance DC, Grand South 1:15 – 5 p.m.

Pan African Urological Surgeons Association (PAUSA), Renaissance DC, Room 12-14

Schedule-at-a-Glance

www. AUA2011.org  


UNLESS OTHERWISE NOTED.

4 p.m.

4:30 p.m.

5 p.m.

5:30 p.m.

6 p.m.

6:30 p.m.

050PG Decision Making in Surgery for Urethral Stricture, 151AB 051PG Coding and Reimbursement Update 2011, 146ABC 052PG Basic and Advanced Laparoscopic and Robotic Oncology: Renal, Prostate, Bladder and Testis (RPLND), 150AB 053PG Infertility Update 2011: A Comprehensive Approach to the Diagnosis and Treatment of the Infertile Male, 144ABC 054PG Primer and Update on Medical Education for the Practicing Urologist, 147AB 055PG Medical and Surgical Management of Female Sexual Dysfunction: Update 2011, 143ABC 056PG Vaginal Reconstructive Surgery, 145AB (Translated in Spanish)

POD34 POD35 POD36 POD37

Bladder Cancer: Basic Research, 101 Infections/Inflammation of the Genitourinary Tract: Kidney & Bladder, 102 Pediatrics: Stone Disease & Tumors, 209ABC Technology & Instruments: Ureteroscopy, 103

MP38 MP39 MP40 MP41 MP42 MP43

Bladder Cancer: Detection and Screening, 202A Kidney Cancer: Localized, 201 Prostate Cancer: Basic Research, 206 Prostate Cancer: Localized, 207B Sexual Function/Dysfunction/Andrology: Evaluation, 207A Urodynamics/Incontinence/Female Urology: Incontinence Evaluation & Therapy, 202B

www.AUA2011.org

   Schedule-at-a-Glance

19


tuesday - morning 6:30 a.m.

7 a.m.

7:30 a.m.

8 a.m.

8:30 a.m.

9 a.m.

7:30 – Noon Hall D

6 – 8 a.m. 057IC PVP: Photoselective KTP/LBO Laser Vaporization of Obstructive BPH, 151AB 058IC Neurological Evaluation of the Urological Patient, 146ABC 059IC Active Surveillance in Prostate Cancer, 144ABC 060IC The Management of Post-Radical Prostatectomy Urinary Incontinence: A Practical Approach, 147AB

Video Sessions

Poster Sessions

Podium Sessions

Courses

Plenary Sessions

6 a.m.

ALL SESSIONS HELD IN WALTER E. WASHINGTON CONVENTION CENTER UNLESS

8:30 – 11:45 a.m. 062PG 063PG 064PG 065PG 066PG 067PG 068PG 8 – 10 a.m.

POD38 Kidney Cancer: Localized, 101 POD39 Sexual Function/Dysfunction/Andrology: Evaluation, POD40 Stone Disease: New Technology/SWL, Ureteroscopic or Percutaneous Stone Removal, 209ABC

8 – 10 a.m.

MP44 Bladder Cancer: Invasive, 206 MP45 Infections/Inflammation of the Genitourinary Tract: MP46 Prostate Cancer: Basic Research, 207B MP47 Prostate Cancer: Localized, 202B MP48 Technology & Instruments: Surgical Education & Skills MP49 Urodynamics/Incontinence/Female Urology: Neurogenic

8 – 10 a.m. Infertility, Infection, Erectile Dysfunction and Trauma

Science & Technology Hall/ Industry Events

9 a.m. – 4 p.m.

9 – 4 p.m.

Int’l Program

20

Schedule-at-a-Glance

www. AUA2011.org  


OTHERWISE NOTED.

21

9:30 a.m.

10 a.m.

10:30 a.m.

11 a.m.

11:30 a.m.

Noon

Lunch & Learn Sessions Tuesday’s Topic: Case Discussions in Sexual Function/Infertility Noon - 1:30 p.m. Science & Technology Hall, #3951 Limited seating! Tickets are $75 and can be purchased in Registration. Featured Experts for Tuesday’s Lunch and Learn

Craig S. Niederberger, MD Wayne J. G. Hellstrom, MD Irwin Goldstein, MD SOLD OUT Culley C. Carson, III, MD SOLD OUT John P. Mulhall, MD SOLD OUT Allen D. Seftel, MD Tom Lue, MD SOLD OUT Drogo K. Montague, MD

Azoospermia: Evaluation, Genetic Considerations, Vasovasostomy, 151AB Prostate Cancer Update 2011, 146ABC Evaluation and Management of Pediatric Voiding Dysfunction, 150AB Robotics: Getting Started, 144ABC Defining the Candidate for Surveillance or Targeted Focal Therapy, 147AB Renal Transplantation: The Global Perspective, 143ABC Optimization of Sexual Function Outcomes in the Prostate Cancer Patient, 145AB

10:30 a.m. – 12:30 p.m. POD41 Bladder Cancer: Superficial, 209ABC POD42 Kidney Cancer: Localized, 101 POD43 Sexual Function/Dysfunction/Andrology: Medical and Non-Surgical Therapy, 102 POD44 Stone Disease: New Technology/SWL, Ureteroscopic or Percutaneous Stone Removal, 103 POD45 Urodynamics/Incontinence/Female Urology: Female Urology, 202B

102

10:30 a.m. – 12:30 p.m. MP50 Benign Prostatic Hyperplasia: Basic Research, 206 MP51 Bladder Cancer: Invasive, 207B MP52 Prostate Cancer: Basic Research, 207A MP53 Prostate Cancer: Localized, 202A

Prostate & Genitalia, 201 Assessment, 207A Voiding Dysfunction, 202A Ballroom A

10:30 a.m. – 12:30 p.m. Pediatrics and Reconstruction, Ballroom A

Science & Technology Hall Open 10 – 11 a.m. Dendreon Corporation, ICU Theater,

Booth 2141

Skills Enhancement Workshops, Booths 217, 417, 425

Noon – 1 p.m. Ferring Pharmaceuticals, Inc., ICU Theater, Booth 2141 Noon – 2 p.m. Residents’ Program – “Healthcare Solutions in the Era of Healthcare Reform” Sponsored by Endo Pharmaceuticals, Salon C

near East Registration

Noon – 5 p.m. Portuguese Urology Program, Ballroom B Noon – 5:30 p.m. SSMR, Grand Hyatt,

Constitution AB

www.AUA2011.org

   Schedule-at-a-Glance


tuesday - afternoon 12:30 p.m.

1 p.m.

1:30 p.m.

ALL SESSIONS HELD IN WALTER E. WASHINGTON CONVENTION CENTER 2 p.m.

3 p.m.

2:30 p.m.

Courses

1 – 3 p.m. 069IC Translational Urology Research: Step-by-Step How to Do It, from Concepts to Getting Funded, 151AB 070IC Update on AUA Cancer-Related Guidelines: Preparation for Certification, 146ABC 071IC Robotic Prostatectomy: Tips and Tricks in Developing a High-Volume, Efficient Program, 144ABC 072IC Geriatric Urology: Basic Principles for Urologic Practice, 147AB 073IC Interstitial Cystitis/Bladder Pain Syndrome: A Primer and a World View, 143ABC 074IC The Use of Robotic Technology in Female Pelvic Floor Reconstruction 145AB

1 – 3 p.m. POD46 Bladder Cancer: Invasive, 209ABC POD47 Kidney Cancer: Localized, 101 POD48 Urodynamics/Incontinence/Female Urology: Female Urology, 102

Podium Sessions Poster Sessions

1 – 3 p.m.

3:30 p.m.

3:15 – 6:30 p.m.

3:30 – 5:30 p.m.

MP54 Benign Prostatic Hyperplasia: Epidemiology and Natural History/Evaluation and Markers, 206 MP55 Bladder Cancer: Superficial, 202A MP56 Kidney Cancer: Advanced, 207B MP57 Prostate Cancer: Localized, 201 MP58 Sexual Function/Dysfunction/Andrology: Peyronie’s Disease/Surgical Therapy, 202B MP59 Stone Disease: New Technology/SWL, Ureteroscopic or Percutaneous Stone Removal, 207A

3:30 – 5:30 p.m.

Video Sessions

1 – 3 p.m. Bladder Cancer & Reconstruction Ballroom A

1 – 3:30 p.m. Late Breaking Science Forum, 103AB

Forums Science & Technology Hall Industry Event Specialty Soc./Int’l Prog.

22

9 a.m. – 4 p.m. Noon – 1 p.m. Ferring Pharmaceuticals, Inc., ICU Theater, Booth 2141

Science & Technology Hall Open – Skills Enhancement Workshops, Booths 217, 417, 425 1:30 – 2:30 p.m. Nymox Pharmaceutical Corporation,

3 – 4 p.m. Accuray Incorporated,

ICU Theater, Booth 2141

ICU Theater, Booth 2141

Noon – 2 p.m. Healthcare Solutions in the Era of Healthcare Reform, Sponsored by Endo Pharmaceuticals, East Salon C by Registration Noon – 1:30 p.m. Lunch & Learn

Noon – 5:30 p.m. Society for the Study of Male Reproduction (SSMR), Grand Hyatt, Constitution AB 1 – 5 p.m. Urologic Society for Transplantation and Renal Surgery (USTRS), Renaissance DC, Renaissance East Noon – 5:00 p.m. Portuguese Urology Program, Ballroom B

Schedule-at-a-Glance

www. AUA2011.org  


UNLESS OTHERWISE NOTED. 4 p.m.

075PG 076PG 077PG 078PG 079PG 080PG 081PG

4:30 p.m.

5 p.m.

5:30 p.m.

6 p.m.

6:30 p.m.

Complications of Laparoscopic and Robotic Urologic Oncologic and Reconstructive Surgery, 151AB Nerve-Sparing Radical Cystectomy and Orthotopic Bladder Substitution, 146ABC Urologic Trauma and Reconstruction, 150AB Medical Malpractice in Urology: How to Prevent and Defend, 144ABC Multidisciplinary Management of Urothelial Carcinoma: Stage and Site-Specific Discussions, 147AB Foundations in Female Urology, 143ABC Common Problems in Pediatric Urology: What Every Urologist Should Know, 145AB (Translated in Spanish)

POD49 Benign Prostatic Hyperplasia: Medical and Hormonal Therapy, 102 POD50 Bladder Cancer: Metastatic Disease, 101 POD51 Kidney Cancer: Advanced, 209ABC

MP60 Bladder Cancer: Staging, 202A MP61 Prostate Cancer: Detection and Screening, 202B MP62 Stone Disease: New Technology/SWL, Ureteroscopic or Percutaneous Stone Removal, 201 MP63 Urodynamics/Incontinence/Female Urology: Non-Neurogenic Voiding Dysfunction, 206

5:30 – 6:30 p.m. Evening Clinical Update – Sanofi-aventis, Salon C by Registration

www.AUA2011.org

   Schedule-at-a-Glance

23


wednesday - Morning 6:30 a.m.

7 a.m.

Plenary Sessions

6 a.m.

ALL SESSIONS HELD IN WALTER E. WASHINGTON CONVENTION

7:30 a.m.

8:30 a.m.

8 a.m.

9 a.m.

7:30 – Noon Hall D

Courses

8:30 – 11:45 a.m. 082PG 083PG 084PG 085PG 086PG 087PG 088PG

Podium Sessions Poster Sessions

8 – 10 a.m. POD52 Transplantation & Vascular Surgery: Renal Transplantation, Vascular Surgery, 209ABC POD53 Urodynamics/Incontinence/Female Urology:

8 – 10 a.m. MP64 Infertility: Physiology, Pathophysiology, Basic Research, MP65 Prostate Cancer: Detection and Screening, 206 MP66 Stone Disease: Basic Research, 207A

Video Sessions

8 – 10 a.m. Single Port Surgery Ballroom A

wednesday - afternoon

Forums

Poster Podium Sessions Sessions

Courses

12:30 p.m.

Industry Event

24

1 p.m.

1:30 p.m.

2 p.m.

3 p.m.

2:30 p.m.

3:30 p.m.

1 – 3 p.m. 089IC Managing Refractory Overactive Bladder Conditions: Translating the Pathophysiology of Refractory Conditions Into Successful Management Outcomes, 151AB 090IC Management of Small Renal Masses, Technical Advances in Partial Nephrectomy and Role of the Urologist in Advanced RCC: A Case-Based Approach, 146ABC 091IC Renal Physiology and Pathophysiology: What You Need to Know for Your Boards and Beyond, 144ABC 092IC The Role of Radical Prostatectomy and Pelvic Lymph Node Dissection in an Integrated Program of Treatment of High-Risk Prostate Cancer, 143ABC 1 – 3 p.m. 1 – 3 p.m. 1 – 2:30 p.m.

POD56 Benign Prostatic Hyperplasia: Surgical Therapy and New Technology, 102 POD57 Infertility: Therapy, 209ABC POD58 Prostate Cancer: Markers, 207B MP71 Imaging/Radiology: Uroradiology, 207A MP72 Stone Disease: Evaluation & Medical Management, 206 MP73 Transplantation & Vascular Surgery: Renal Transplantation, Vascular Surgery, 201

3:30 – 5:30 p.m.

Global Perspectives in Urology Forum, 103AB

12:30 – 1:30 p.m. “How Can We Improve Management of Non-Muscle Invasive Bladder Cancer?” Sponsored by GE Healthcare, 147

Schedule-at-a-Glance

www. AUA2011.org  


CENTER UNLESS OTHERWISE NOTED. 9:30 a.m.

10 a.m.

10:30 a.m.

11 a.m.

11:30 a.m.

25

Noon

Evidence-Based Decision Making in Urology: Assessing the Quality of Evidence Using GRADE, 151AB Minimally Invasive Ablative Treatment of Prostate Cancer, 146ABC Nephron-Sparing Renal Surgery: New Techniques and Latest Developments, 150AB Practical Follow-Up of Genitourinary Malignancies, 144ABC New Imaging Technologies for Intraoperative Surgical Navigation During Urologic Surgery: Current Status and Future Trends, 147AB Challenges in the Evaluation and Management of Post-Prostatectomy Incontinence in the 21st Century, 143ABC Urethral Reconstruction, 145AB 10:30 a.m. – 12:30 p.m. POD54 Infertility: Evaluation, 102 POD55 Transplantation & Vascular Surgery: Renal Transplantation, Vascular Surgery,

Pelvic Prolapse, 102

209ABC

10:30 a.m. – 12:30 p.m. MP67 MP68 MP69 MP70

207B

4 p.m.

4:30 p.m.

5 p.m.

Benign Prostatic Hyperplasia: Surgical Therapy and New Technology, 207B Prostate Cancer: Detection and Screening, 201 Stone Disease: Basic Research, 206 Urodynamics/Incontinence/Female Urology: Urodynamic Testing, 207A

thursday - MORNING Plenary Sessions

7 a.m.

8 a.m.

9 a.m.

10 a.m.

11 a.m.

Noon

7:30 a.m. – Noon Take-Home Messages, Hall D

MP74 Imaging/Radiology: Uroradiology, 207B MP75 Prostate Cancer: Markers, 206

www.AUA2011.org

   Schedule-at-a-Glance


26

Research. Progress. Cures. Research. Progress. Cures. Working for the Future of Urology Health

NURA

National Urology Research Agenda A roadmap for priorities in urologic disease research.

Working for the Future of Urology Health

The AUA Foundation’s National Urology Research Agenda (NURA) provides the first comprehensive roadmap for urology research by identifying key areas that need to be addressed in order to advance progress.

Visit us at booth 2019 and get your copy today or visit us online at UrologyHealth.org.

AUA Skills Enhancement Workshops in Science & Technology Hall – the place to go to enhance your hands-on skills and get the latest in technology and training from leaders in urology! The Skills Enhancement Workshop area is located in Hall C of the Science & Technology Hall, and programs are offered daily during exhibit hours. Featured programs include: American Medical Systems, Booth 217: Greenlight: Turning the Gold Standard Green with Envy

Cook Medical, Booth 425: Flexible Ureteroscopy for the Treatment of Renal Calculi: Work shoulder-to-shoulder with our world-renowned faculty to sharpen your skills in minimally invasive stone management techniques.

Boston Scientific Corporation, Booth 417: The Hybrid Technique: Combining HoLAP and HoLEP for the Treatment of BPH

Science & Technology Hall Hours: Saturday 11-6 Sunday 9-4 Monday 9-4 Tuesday 9-4

These are just some of the sessions offered; check your AUA Pocket Planner and Daily Schedule for a complete list of events!


What really killed the Father of our Country?

Booth #2713

Supported by


Course Digital Library Every recorded course. Every available speaker slide. Special Onsite Pricing! $199 Order onsite at the AUA Annual Meeting and save $100! Post Annual Meeting Pricing: $299

- Synchronized slides with audio - Access on your mobile device or desktop - Access Greenroom™ to discuss course materials with colleagues

Download at the Apple App Store or Android Market!

To learn more or to purchase, visit the Course Digital Library Booth outside Room 156.


Our knowledge.

{

Our patients’ lives.

Save the Date! AUA Annual Meeting May 19–24, 2012 Atlanta, GA

Visit AUA2012.org


PROVENGE® (sipuleucel-T) Suspension for Intravenous Infusion

Rx Only

BRIEF SUMMARY — See full Prescribing Information for complete product information INDICATIONS AND USAGE: PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. DOSAGE AND ADMINISTRATION • For Autologous Use Only. • The recommended course of therapy for PROVENGE is 3 complete doses, given at approximately 2-week intervals. • Premedicate patients with oral acetaminophen and an antihistamine such as diphenhydramine. • Before infusion, confirm that the patient’s identity matches the patient identifiers on the infusion bag. • Do Not Initiate Infusion of Expired Product. • Infuse PROVENGE intravenously over a period of approximately 60 minutes. Do Not Use a Cell Filter. • Interrupt or slow infusion as necessary for acute infusion reactions, depending on the severity of the reaction. (See Dosage and Administration [2] of full Prescribing Information.) CONTRAINDICATIONS: None. WARNINGS AND PRECAUTIONS • PROVENGE is intended solely for autologous use. • Acute infusion reactions (reported within 1 day of infusion) included, but were not limited to, fever, chills, respiratory events (dyspnea, hypoxia, and bronchospasm), nausea, vomiting, fatigue, hypertension, and tachycardia. In controlled clinical trials, 71.2% of patients in the PROVENGE group developed an acute infusion reaction. In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. The incidence of severe events was greater following the second infusion (2.1% vs 0.8% following the first infusion), and decreased to 1.3% following the third infusion. Some (1.2%) patients in the PROVENGE group were hospitalized within 1 day of infusion for management of acute infusion reactions. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group. Closely monitor patients with cardiac or pulmonary conditions. In the event of an acute infusion reaction, the infusion rate may be decreased, or the infusion stopped, depending on the severity of the reaction. Appropriate medical therapy should be administered as needed. • Handling Precautions for Control of Infectious Disease. PROVENGE is not routinely tested for transmissible infectious diseases. Therefore, patient leukapheresis material and PROVENGE may carry the risk of transmitting infectious diseases to health care professionals handling the product. Universal precautions should be followed. • Concomitant Chemotherapy or Immunosuppressive Therapy. Use of either chemotherapy or immunosuppressive agents (such as systemic corticosteroids) given concurrently with the leukapheresis procedure or PROVENGE has not been studied. PROVENGE is designed to stimulate the immune system, and concurrent use of immunosuppressive agents may alter the efficacy and/or safety of PROVENGE. Therefore, patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue immunosuppressive agents prior to treatment with PROVENGE. • Product Safety Testing. PROVENGE is released for infusion based on the microbial and sterility results from several tests: microbial contamination determination by Gram stain, endotoxin content, and in-process sterility with a 2-day incubation to determine absence of microbial growth. The final (7-day incubation) sterility test results are not available at the time of infusion. If the sterility results become positive for microbial contamination after PROVENGE has been approved for infusion, Dendreon will notify the treating physician. Dendreon will attempt to identify the microorganism, perform antibiotic sensitivity testing on recovered microorganisms, and communicate the results to the treating physician. Dendreon may request additional information from the physician in order to determine the source of contamination. (See Warnings and Precautions [5] of full Prescribing Information.) ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety evaluation of PROVENGE is based on 601 prostate cancer patients in the PROVENGE group who underwent at least 1 leukapheresis procedure in four

randomized, controlled clinical trials. The control was non-activated autologous peripheral blood mononuclear cells. The most common adverse events, reported in patients in the PROVENGE group at a rate ≥15%, were chills, fatigue, fever, back pain, nausea, joint ache, and headache. Severe (Grade 3) and life-threatening (Grade 4) adverse events were reported in 23.6% and 4.0% of patients in the PROVENGE group compared with 25.1% and 3.3% of patients in the control group. Fatal (Grade 5) adverse events were reported in 3.3% of patients in the PROVENGE group compared with 3.6% of patients in the control group. Serious adverse events were reported in 24.0% of patients in the PROVENGE group and 25.1% of patients in the control group. Serious adverse events in the PROVENGE group included acute infusion reactions (see Warnings and Precautions), cerebrovascular events, and single case reports of eosinophilia, rhabdomyolysis, myasthenia gravis, myositis, and tumor flare. PROVENGE was discontinued in 1.5% of patients in Study 1 (PROVENGE group n=341; Control group n=171) due to adverse events. Some patients who required central venous catheters for treatment with PROVENGE developed infections, including sepsis. A small number of these patients discontinued treatment as a result. Monitoring for infectious sequelae in patients with central venous catheters is recommended. Each dose of PROVENGE requires a standard leukapheresis procedure approximately 3 days prior to the infusion. Adverse events that were reported ≤1 day following a leukapheresis procedure in ≥5% of patients in controlled clinical trials included citrate toxicity (14.2%), oral paresthesia (12.6%), paresthesia (11.4%), and fatigue (8.3%). Table 1 provides the frequency and severity of adverse events reported in ≥5% of patients in the PROVENGE group of randomized, controlled trials of men with prostate cancer. The population included 485 patients with metastatic castrate resistant prostate cancer and 116 patients with non-metastatic androgen dependent prostate cancer who were scheduled to receive 3 infusions of PROVENGE at approximately 2-week intervals. The population was age 40 to 91 years (median 70 years), and 90.6% of patients were Caucasian. Table 1 Incidence of Adverse Events Occurring in ≥5% of Patients Randomized to PROVENGE PROVENGE (N = 601)

Any Adverse Event Chills Fatigue Fever Back pain Nausea Joint ache Headache Citrate toxicity Paresthesia Vomiting Anemia Constipation Pain Paresthesia oral Pain in extremity Dizziness Muscle ache Asthenia Diarrhea Influenza-like illness Musculoskeletal pain Dyspnea Edema peripheral Hot flush Hematuria Muscle spasms

Control* (N = 303)

All Grades n (%)

Grade 3-5 n (%)

All Grades n (%)

591 (98.3) 319 (53.1) 247 (41.1) 188 (31.3) 178 (29.6) 129 (21.5) 118 (19.6) 109 (18.1) 89 (14.8) 85 (14.1) 80 (13.3) 75 (12.5) 74 (12.3) 74 (12.3) 74 (12.3) 73 (12.1) 71 (11.8) 71 (11.8) 65 (10.8) 60 (10.0) 58 (9.7) 54 (9.0) 52 (8.7) 50 (8.3) 49 (8.2) 46 (7.7) 46 (7.7)

186 (30.9) 13 (2.2) 6 (1.0) 6 (1.0) 18 (3.0) 3 (0.5) 11 (1.8) 4 (0.7) 0 (0.0) 1 (0.2) 2 (0.3) 11 (1.8) 1 (0.2) 7 (1.2) 0 (0.0) 5 (0.8) 2 (0.3) 3 (0.5) 6 (1.0) 1 (0.2) 0 (0.0) 3 (0.5) 11 (1.8) 1 (0.2) 2 (0.3) 6 (1.0) 2 (0.3)

291 (96.0) 33 (10.9) 105 (34.7) 29 (9.6) 87 (28.7) 45 (14.9) 62 (20.5) 20 (6.6) 43 (14.2) 43 (14.2) 23 (7.6) 34 (11.2) 40 (13.2) 20 (6.6) 43 (14.2) 40 (13.2) 34 (11.2) 17 (5.6) 20 (6.6) 34 (11.2) 11 (3.6) 31 (10.2) 14 (4.6) 31 (10.2) 29 (9.6) 18 (5.9) 17 (5.6)

Grade 3-5 n (%) 97 (32.0) 0 (0.0) 4 (1.3) 3 (1.0) 9 (3.0) 0 (0.0) 5 (1.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 7 (2.3) 3 (1.0) 3 (1.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 2 (0.7) 3 (1.0) 0 (0.0) 3 (1.0) 3 (1.0) 1 (0.3) 1 (0.3) 3 (1.0) 0 (0.0)

(Table 1 continued on next page.)


Table 1 Incidence of Adverse Events Occurring in ≼5% of Patients Randomized to PROVENGE PROVENGE (N = 601)

Hypertension Anorexia Bone pain Upper respiratory tract infection Insomnia Musculoskeletal chest pain Cough Neck pain Weight decreased Urinary tract infection Rash Sweating Tremor

Control* (N = 303)

All Grades n (%)

Grade 3-5 n (%)

All Grades n (%)

Grade 3-5 n (%)

45 (7.5) 39 (6.5) 38 (6.3) 38 (6.3)

3 (0.5) 1 (0.2) 4 (0.7) 0 (0.0)

14 (4.6) 33 (10.9) 22 (7.3) 18 (5.9)

0 (0.0) 3 (1.0) 3 (1.0) 0 (0.0)

37 (6.2) 36 (6.0)

0 (0.0) 2 (0.3)

22 (7.3) 23 (7.6)

1 (0.3) 2 (0.7)

35 (5.8) 34 (5.7) 34 (5.7) 33 (5.5) 31 (5.2) 30 (5.0) 30 (5.0)

0 (0.0) 3 (0.5) 2 (0.3) 1 (0.2) 0 (0.0) 1 (0.2) 0 (0.0)

17 (5.6) 14 (4.6) 24 (7.9) 18 (5.9) 10 (3.3) 3 (1.0) 9 (3.0)

0 (0.0) 2 (0.7) 1 (0.3) 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0)

*Control was non-activated autologous peripheral blood mononuclear cells.

Cerebrovascular Events. In controlled clinical trials, cerebrovascular events, including hemorrhagic and ischemic strokes, were reported in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group. (See Adverse Reactions [6] of full Prescribing Information.)

To report SUSPECTED ADVERSE REACTIONS, contact Dendreon Corporation at 1-877-336-3736 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Dendreon Corporation 3005 First Avenue Seattle, Washington 98121

Š2010 Dendreon Corporation. All rights reserved. November 2010. Printed in the U.S.A. Dendreon, the Dendreon logo, and PROVENGE are registered trademarks of Dendreon Corporation. P-A-11.10-073.00


Please join us for breakfast and the clinical presentation:

Immunotherapy for the Treatment of

Advanced Prostate Cancer Tuesday, May 17, 2011 10:00 – 11:00 am Industry Clinical Update Theater AUA Science & Technology Hall Booth 2141 Please join us for an interactive discussion on the treatment of advanced prostate cancer and the Phase 3 trial results of an approved immunotherapy.

Presented by:

Paul Schellhammer, MD, FACS Professor of Urology, Eastern Virginia Medical School Medical Director, Virginia Prostate Center

Sponsored by:

©2011 Dendreon Corporation. All rights reserved. March 2011. Printed in the U.S.A. Dendreon, the Dendreon logo, and PROVENGE are registered trademarks of Dendreon Corporation. MA-0001.07

Coordinated by: ®

2011 AUA Schedule-at-a-Glance  

2011 AUA Schedule-at-a-Glance

2011 AUA Schedule-at-a-Glance  

2011 AUA Schedule-at-a-Glance